根据初步未经审计的销售结果，伊芙美尔医疗（ImmuCell）在2026年第一季度实现了产品销售额的显著增长，增幅高达28.4%。这一积极表现凸显了公司核心业务的强劲势头和市场需求的持续扩张。
公司此次披露的初步数据，尽管尚未经过最终审计，但已清晰反映出其主打产品的市场竞争力与销售动能。销售额的大幅提升，为公司在2026财年的开局奠定了坚实的财务基础。
根据初步未经审计的销售结果，伊芙美尔医疗（ImmuCell）在2026年第一季度实现了产品销售额的显著增长，增幅高达28.4%。这一积极表现凸显了公司核心业务的强劲势头和市场需求的持续扩张。
公司此次披露的初步数据，尽管尚未经过最终审计，但已清晰反映出其主打产品的市场竞争力与销售动能。销售额的大幅提升，为公司在2026财年的开局奠定了坚实的财务基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.